Esproquin is an α2-adrenergic receptor agonist derived from tetrahydroisoquinoline.[1] It has a positive inotropic effect, suggesting potential use in treatment of chronic heart failure.[2]

Esproquin
Clinical data
Other namesEsproquine
Legal status
Legal status
  • Investigational
Identifiers
  • 2-(3-Ethylsulfinylpropyl)-3,4-dihydro-1H-isoquinoline
CAS Number
PubChem CID
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H21NOS
Molar mass251.39 g·mol−1
3D model (JSmol)
  • O=S(CC)CCCN1CC=2C=CC=CC2CC1

References

edit
  1. ^ Gray AP, Shiley RH (July 1973). "Preparation and cardiovascular actions of a group of tetrahydroisoquinoline derivatives". Journal of Medicinal Chemistry. 16 (7): 859–61. doi:10.1021/jm00265a028. PMID 4146907.
  2. ^ Kotelanski B, Grozmann RJ, Cohn JN (1973). "Positive inotropic effect of oral esproquin in normal subjects". Clinical Pharmacology and Therapeutics. 14 (3): 427–33. doi:10.1002/cpt1973143427. PMID 4698571. S2CID 46266823.